$1.39 Billion in Sales Expected for Syneos Health, Inc. (NASDAQ:SYNH) This Quarter

Wall Street analysts forecast that Syneos Health, Inc. (NASDAQ:SYNHGet Rating) will report sales of $1.39 billion for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Syneos Health’s earnings. The lowest sales estimate is $1.38 billion and the highest is $1.39 billion. Syneos Health posted sales of $1.28 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.6%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Syneos Health will report full-year sales of $5.66 billion for the current fiscal year, with estimates ranging from $5.61 billion to $5.71 billion. For the next financial year, analysts expect that the company will report sales of $6.14 billion, with estimates ranging from $6.05 billion to $6.22 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Syneos Health.

Syneos Health (NASDAQ:SYNHGet Rating) last released its earnings results on Friday, April 29th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.95 by $0.06. Syneos Health had a return on equity of 13.33% and a net margin of 4.54%. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The firm’s revenue was up 10.5% on a year-over-year basis.

SYNH has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Syneos Health in a research note on Monday, April 11th. They issued a “buy” rating and a $102.00 price objective for the company. Mizuho reduced their price objective on Syneos Health from $109.00 to $94.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Jefferies Financial Group cut Syneos Health from a “buy” rating to a “hold” rating and reduced their price objective for the company from $101.00 to $75.00 in a research note on Monday, April 25th. StockNews.com assumed coverage on Syneos Health in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Barclays dropped their target price on Syneos Health from $115.00 to $105.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $100.33.

Shares of Syneos Health stock opened at $73.79 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.07 and a current ratio of 1.09. Syneos Health has a 52 week low of $66.77 and a 52 week high of $104.18. The stock has a 50 day moving average price of $78.29 and a two-hundred day moving average price of $88.36. The stock has a market capitalization of $7.57 billion, a PE ratio of 31.94 and a beta of 1.79.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Syneos Health by 7.7% during the fourth quarter. BlackRock Inc. now owns 9,910,450 shares of the company’s stock worth $1,017,605,000 after acquiring an additional 707,665 shares during the period. State Street Corp lifted its holdings in Syneos Health by 3.3% during the fourth quarter. State Street Corp now owns 2,599,069 shares of the company’s stock worth $266,872,000 after acquiring an additional 82,093 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Syneos Health by 42.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,200,361 shares of the company’s stock worth $192,488,000 after acquiring an additional 653,520 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Syneos Health by 3.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,806,401 shares of the company’s stock worth $158,024,000 after acquiring an additional 59,129 shares during the period. Finally, GW&K Investment Management LLC lifted its holdings in Syneos Health by 2.0% during the fourth quarter. GW&K Investment Management LLC now owns 1,611,918 shares of the company’s stock worth $165,511,000 after acquiring an additional 31,598 shares during the period. Institutional investors and hedge funds own 98.38% of the company’s stock.

About Syneos Health (Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Read More

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.